China
Africa
Explore chapters and articles related to this topic
Epilepsy
Published in Philip B. Gorelick, Fernando D. Testai, Graeme J. Hankey, Joanna M. Wardlaw, Hankey's Clinical Neurology, 2020
Donald C. Barr, Andres M. Kanner
At the completion of the benzodiazepine load, and within 30 minutes of the start of therapy, the patient is concurrently started on a second-line therapy for prevention of withdrawal. Most algorithms suggest: Levetiracetam at a dose of 40–60 mg/kg.Lacosamide at a dose of 400–600 mg/day.Valproic acid at a dose of 30–40 mg/kg, if seizures continue, an additional 10 mg/kg may be given.Phenytoin (usually administered as fosphenytoin due to the lower risk of cardiovascular side effects) at 20 mg/kg loading dose.
Antiepileptic and antiarrhythmic agents
Published in Peter R Wilson, Paul J Watson, Jennifer A Haythornthwaite, Troels S Jensen, Clinical Pain Management, 2008
A single randomized placebo-controlled trial of 119 patients with diabetic neuropathy showed superiority of lacosamide, a third generation novel AED, over placebo.87[II] Adverse effects were mostly mild or moderate with CNS-related effects (dizziness, nausea, and anxiety) more common with lacosamide. Despite borderline efficacy, its relative tolerability associated with probably a novel mode of action, justifies larger trials.
The adverse-effect profile of lacosamide
Published in Expert Opinion on Drug Safety, 2020
Jiyuan Li, Meizhen Sun, Xuefeng Wang
Lacosamide was approved in 2008 for adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in adults. In 2011, the drug was marketed in Europe. The current indications have been extended to adolescents and children aged 4 years and older [15]. Lacosamide as monotherapy could be effective and well tolerated in adult patients with partial-onset seizures who had successfully responded to add-on therapy after failure of previous treatment [16]. Its monotherapy also has an acceptable effect in other adult patient populations [17,18]. Furthermore, lacosamide provided a promising adjunctive therapy in children affected by Lennox-Gastaut Syndrome and refractory focal epilepsy [19,20], and its intravenous use in patients with status epilepticus may have an exciting prospect [21]. Svendsen T et al. [22] evaluated the pharmacokinetic variability of LCM in relation to efficacy and tolerability, and this drug performed well in patients with refractory epilepsy. In more than 10 years of use since the effectiveness of lacosamide was established, its adverse reactions have gradually been discovered.
Lacosamide as a first-line treatment option in focal epilepsy: a cost-utility analysis for the Greek healthcare system
Published in Journal of Medical Economics, 2019
Mary Geitona, Eugena Stamuli, Stylianos Giannakodimos, Vasileios K. Kimiskidis, Vasileios Kountouris, Mata Charokopou, Petros Christou
Treatment with lacosamide is shown to be a cost-effective option compared to zonisamide at a willingness-to-pay threshold far below the acceptable ICER threshold of €30,000 per QALY. Hence, it represents a valuable monotherapy option for the treatment of newly diagnosed and early stage patients with focal epileptic seizures. Lacosamide provides patients with day-to-day control of their lives via sustainable and tolerable seizure control and leads to improvements in patients’ quality-of-life. These findings need to be taken into consideration by the Greek healthcare decision-makers, as they can lead to a better allocation of resources in the healthcare sector.
Neonatal seizures treatment based on conventional multichannel EEG monitoring: an overview of therapeutic options
Published in Expert Review of Neurotherapeutics, 2022
Isotta Guidotti, Licia Lugli, Luca Ori, Maria Federica Roversi, Elisa Della Casa Muttini, Luca Bedetti, Marisa Pugliese, Francesca Cavalleri, Francesca Stefanelli, Fabrizio Ferrari, Alberto Berardi
Intravenous lacosamide has recently been reported as an adjunctive therapy to treat super-refractory neonatal SE without adverse effects [94]. Lacosamide lacks potential interactions, has a good tolerability, and can be administered intravenously. Available data regarding its use in adults and children are promising.